Zai Lab raises $250 million via private placement, discloses new zoci data

Zai Lab Limited disclosed in an 8-K dated October 22, 2026 that it had entered into a securities purchase agreement with accredited investors for the sale of 11,340,000 American depositary shares, each representing ten ordinary shares, at an offering price of $22.04 per ADS in a private placement transaction¹.

The company said it expects to receive proceeds of approximately $250 million before fees and expenses, which it intends to use to fund pipeline development and for working capital and other general corporate purposes¹. Closing of the placement is expected on or about October 27, 2026, subject to customary closing conditions.¹ Zai Lab also agreed to file an initial registration statement with the SEC within 15 days of closing to register the ADSs for resale¹.

Alongside the financing, Zai Lab published an updated corporate presentation on October 23, 2026, filed as Exhibit 99.1 to the 8-K¹. The presentation included new data on zocilurtatug pelitecan (zoci, ZL-1310), a DLL3-targeting antibody-drug conjugate. In a first-line small cell lung cancer cohort combining zoci with atezolizumab, the company reported an 81.8% confirmed objective response rate in 1L SCLC with a chemo-free regimen of 1.6 mg/kg zoci plus atezolizumab¹. On duration of response, the presentation noted a 97.1% rate of responders achieving response at the first post-baseline tumor assessment, with median duration of response not reached¹. For progression-free survival, the data showed a 6-month PFS rate of 81.9% at a median follow-up of 4.6 months.¹

The presentation also noted that Amgen sponsors and leads a global Phase 1b study while Boehringer Ingelheim sponsors and leads a global Phase 1b/2 study, with Zai Lab supplying study drug in both¹. Separately, the company said its cash position stood at $718 million as of Q2 2026¹.